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Context: PAPSS2 (PAPS synthase 2) provides the universal sulfate donor PAPS (3-phospho-aden-
osine-5-phosphosulfate) to all human sulfotransferases, including SULT2A1, responsible for sul-
fation of the crucial androgen precursor dehydroepiandrosterone (DHEA). Impaired DHEA sulfa-
tion is thought to increase the conversion of DHEA toward active androgens, a proposition
supported by the previous report of a girl with inactivating PAPSS2mutationswho presentedwith
low serumDHEA sulfate andandrogenexcess, clinicallymanifestingwithpremature pubarche and
early-onset polycystic ovary syndrome.
Patients andMethods:We investigated a family harboring twonovel PAPSS2mutations, including
two compound heterozygous brothers presentingwith disproportionate short stature, low serum
DHEAsulfate,butnormal serumandrogens.PatientsandparentsunderwentaDHEAchallengetest
comprising frequent blood sampling and urine collection before and after 100 mg DHEA orally,
with subsequent analysis of DHEA sulfation and androgenmetabolism bymass spectrometry. The
functional impact of the mutations was investigated in silico and in vitro.
Results:We identified a novel PAPSS2 frameshift mutation, c.1371del, p.W462Cfs*3, resulting in
complete disruption, and a novel missense mutation, c.809GA, p.G270D, causing partial disrup-
tion of DHEA sulfation. Both patients and their mother, who was heterozygous for p.W462Cfs*3,
showed increased 5-reductase activity at baseline and significantly increasedproductionof active
androgens after DHEA intake. The mother had a history of oligomenorrhea and chronic anovu-
lation that required clomiphene for ovulation induction.
Conclusions: We provide direct in vivo evidence for the significant functional impact of mutant
PAPSS2 on DHEA sulfation and androgen activation. Heterozygosity for PAPSS2mutations can be
associated with a phenotype resembling polycystic ovary syndrome. (J Clin Endocrinol Metab 100:
E672–E680, 2015)
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Abbreviations: An/Et, androsterone/etiocholanolone; BMI, body mass index; DHEA, dehy-
droepiandrosterone; DHEAS, DHEA sulfate; DHT, 5-dihydrotestosterone; MAF, minor
allele frequency; PAPS, 3-phospho-adenosine-5-phosphate; PAPSS2, PAPS synthase 2;
PCOS, polycystic ovary syndrome; SDS, standard deviation score; SEMD, spondyloepime-
taphyseal dysplasia.
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Dehydroepiandrosterone (DHEA) can be converted toits inactive sulfate ester,DHEA sulfate (DHEAS), or
toward active androgens via androstenedione andT to the
most potent androgen, 5-dihydrotestosterone (DHT). It
was previously assumed that DHEA andDHEAS are con-
tinuously interconverted, with DHEAS serving as a circu-
lating pool for reactivation to DHEA, and ultimately sex
steroids. However, this concept was called into question
by studies suggesting that DHEA sulfation by the enzyme
DHEAsulfotransferase, SULT2A1, is the predominant re-
action, and the conversion back to DHEA through the
enzyme steroid sulfatase is only a rare occurrence (1, 2),
except for distinct tissues with ample steroid sulfatase ac-
tivity, such as placenta and cancers of prostate, breast,
endometrium, and colon (3).
We previously described a female patient with clinical
and biochemical evidence of androgen excess and concur-
rently very low serum DHEAS (4). She presented with
premature pubarche at 6 years of age and then progressed
to a clinically overt polycystic ovary syndrome (PCOS)
phenotype, with acne, hirsutism, and eventually second-
ary amenorrhea at the age of 13 years. We hypothesized
that impaired DHEA sulfation would explain the concur-
rent findings of low DHEAS and increased active andro-
gens. Genetic analysis revealed compound heterozygous
mutations in thePAPSS2 gene encoding human PAPS syn-
thase 2, which provides the sulfate donor PAPS (3=-phos-
pho-adenosine-5=-phosphosulfate) to all human sulfo-
transferases including SULT2A1 (Figure 1A). Functional
in vitro analysis of the mutant PAPSS2 proteins demon-
strated significantly impaired DHEA sulfation (4).
Interestingly, homozygous PAPSS2 mutations had al-
ready been described in 1998 in a consanguineous Pakistani
family presenting with spondyloepimetaphyseal dysplasia
(SEMD) (5, 6), a subgroup of the large and heterogeneous
group of bone dysplasias (7), whereas no clinically overt
bone phenotype was found in our female patient (4), with
only mild radiological evidence of platyspondyly within the
thoracic spine. The individuals in the Pakistani family, 11
men and five women, did not undergo endocrine investiga-
tions, and no access was granted to the women for clinical
assessment. Three recent papers have described 24 addi-
tional individualswithPAPSS2deficiency (8–10),allof them
presenting with clinically overt bone dysplasia. However,
serum androgens weremeasured in only five of them, unan-
imously revealing lowDHEASbut normal circulating active
androgens.
Here we have studied the biochemical and clinical con-
sequences of PAPSS2 deficiency in a family with two
brothers compound heterozygous for two novel PAPSS2
mutations, who presented with clinically overt SEMD,
low serumDHEAS, but normal serumandrogens.We car-
ried out an integrated in silico and in vitro mutation anal-
ysis as well as detailed in vivo studies of DHEA sulfation
capacity and androgen synthesis in the patients and their
heterozygous parents.
Patients and Methods
Patients
The first index case, P1, was born after an uneventful preg-
nancy at 37weeks gestation (birthweight, 2580g;1.0 SDscore
[SDS]); birth length not recorded). Short stature with dispropor-
tionately short arms and legs was noticed during the first few
months after birth. Psychomotor development was normal. At
4.6 years of age, he underwent detailed review by a clinical ge-
neticist, documenting disproportionate growth and short stature
with scoliosis, consistent with the phenotypic features of SEMD.
His growth curve is shown in Supplemental Figure 1A.A skeletal
survey showed scoliosis, platyspondyly with coronal clefts, hor-
izontal acetabular roofs with small iliac wings, small femoral
epiphyses, and slight metaphyseal changes, but normal hands
(Supplemental Figure 2, A–D).
The patient reported normal age of pubarche (Tanner stage
P2 at 12.5 y). At the age of 17.6 years, his height was 145.8 cm
(5.0 SDS), weight was 48.2 kg (body mass index [BMI], 0.7
SDS), head circumference was 56.8 cm (0.1 SDS), arm span
was 150.8 cm, sitting height was 78.5 cm, providing a sitting
height/height ratioof0.54 (1.9SDS), andhisboneagewas15.5
years. Pubertal developmentwasnormal (Tanner stageA2P5G5;
testicular volume, 25 mL bilaterally). Serum DHEAS was de-
tectable but low (0.5 mol/L; male reference range, 2.0–15.0
Figure 1. In silico analysis of the mutant PAPSS2 proteins. A, Either
DHEA is converted via to T and DHT, activating the androgen receptor,
or DHEA is sulfated by DHEA sulfotransferase (SULT2A1), which
requires provision of the universal sulfate donor PAPS, generated by
successive ATP sulfurylase and APS kinase activities of PAPSS2.
A, androstenedione; APS, adenosine 5-phosphosulfate; PAPS,
3-phosphoadenosine 5-phosphosulfate; PAP, 3-phosphoadenosine
5-phosphate; PPi, pyrophosphate. B and C, Homology model of
human PAPSS2 based on the 1XNJ structure of PAPSS1 (12), with one
high-affinity dimer represented in gray, the other in cyan, visualizing
protein truncation by the frameshift mutation p.W462Cfs*3 (B) and
the glycine residue affected by the missense mutation p.G270D (C).
doi: 10.1210/jc.2014-3556 jcem.endojournals.org E673
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 07 May 2015. at 04:19 For personal use only. No other uses without permission. . All rights reserved.
mol/L); serum and T were within the reference range (Supple-
mental Table 1).
His brother, P2, who was 2.5 years younger, was found to
have short extremities upon prenatal ultrasound.Hewas born at
38 weeks gestation (birth weight, 2860 g [0.8 SDS]; length not
recorded). Psychomotor development was normal. His growth
curve is shown in Supplemental Figure 1B. Age of pubarche was
normal (12–13 y). A skeletal survey showed skeletal abnormal-
ities similar to his brother, P1 (Supplemental Figure 2, E–H). At
the ageof15.1years, his heightwas143.3 cm(4.1SDS),weight
was 45.3 kg (BMI, 1.3 SDS), span was 150.0 cm, sitting height
was 73.7 cm (sitting height/height ratio,0.3 SDS), andhis bone
age was 13.5 years. Pubertal development was normal (Tanner
stage A1P4G4; testicular volume, 14 mL bilaterally). Serum
DHEASwas low (0.44mol/L); circulating androgenswere nor-
mal (Supplemental Table 1).
The nonconsanguineous parents had normal body propor-
tions and height (father, 183 cm, 0.1 SDS; mother, 168 cm,
0.4 SDS). The 43-year-old mother reported a normal age of
menarche (13 y), but irregular periods from the start. Due to
anovulatory oligomenorrhea, all her pregnancies were only
achieved after ovulation induction with clomiphene. She did not
suffer from acne or hirsutism, and her ovaries did not appear
polycystic upon imaging. At the age of 40 years, she developed
psoriatic arthritis, and subsequently intolerance to several drugs
was noted (for details, see Supplemental Data).
Theolder sisterof the two indexpatientswasofnormalheight
(166 cm,0.7 SDS) and weight (BMI, 23.2 kg/m2 at 19 years);
however, she had failed to develop a spontaneous menarche and
therefore had been initiated on oral contraceptives for cycle reg-
ulation at 13 years of age.
Genetic analysis
Exome sequencing was undertaken after obtaining appropri-
ate informed consent. Genomic DNAwas isolated from periph-
eral blood using the AUTOPURE LS Instrument (Gentra Sys-
tems). Cytogenetic microarray analysis was performed using the
CytoScan HD Array (Affymetrix) according to the manufactur-
er’s protocol. Copy number was assessed using Chromosome
Analysis Suite software (Affymetrix). Whole exome sequencing
was performed on DNA fragmented into 200- to 400-bp frag-
ments using Adaptive Focused Acoustics (Covaris Inc) shearing
according to the manufacturer’s instructions. The exome was
captured by Nimblegen SeqCap EZ V2 kit (Roche Nimblegen,
Inc) in combinationwith Illumina paired end library preparation
and 2  100 bp sequencing with at least 70x mean coverage.
Downstream analyses included demultiplexing (CASAVA soft-
ware; Illumina Inc), sequence quality control, capture quality
control, single nucleotide polymorphism calling, and indel (in-
sertions and deletions) calling using different software applica-
tions as described by Santen (11). Identifiedmutationswere con-
firmed by Sanger sequencing (primer sequences available on
request).
In silico modeling of the mutant PAPSS2 protein
Ahomologymodel of humanPAPSS2wasbuilt on the known
crystal structure 1XNJ of PAPSS1 (12), as described previously
(13), and the affected Gly270 residue was visualized using
YASARA (14). A sequence alignment of 101 vertebrate and in-
vertebrate sequences (15) was extended to plant, fungal, and
yeast sequences of ATP sulfurylase. The alignment was created
using Clustal W (16).
In vitro functional analysis of the mutant PAPSS2
proteins
Expression vectors containing the human PAPSS2 coding
sequence harboring the newly identified mutations were cre-
ated by site-directed mutagenesis with DpnI selection in the
pcDNA6 and pEGFP-N1 vector backgrounds, as previously
described (17).
To assess the impact of the mutant proteins on DHEA sulfa-
tion, an in-house clone of HEK293 cells with very low endoge-
nous PAPSS2 and SULT2A1 expression was cotransfected with
PAPSS2andSULT2A1; in addition towild-typePAPSS2and the
two novel PAPSS2 mutants, we expressed the previously de-
scribed p.T48Rmutant (4) for comparison.Cellswere incubated
with 250 nMDHEA and 0.2Ci 3H-DHEA for 2 hours at 37°C;
all assayswere performed in triplicate. Steroidswere extracted as
previously described (4) and analyzed on a LablogicAR2000
bioscanner. The conversion rate observed after expression of
SULT2A1 alone was subtracted from those observed after
coexpression with PAPSS2. For SULT2A1 detection by West-
ern blotting, we used a polyclonal rabbit antibody ab38416
(Abcam), employing the horseradish peroxidase-linked -actin
monoclonal antibody ab20272 (Abcam) for confirmation of
equal loading. PAPSS2 protein expressionwas tested using the
anti-PAPSS2 monoclonal antibody ab56393 (Abcam) raised
against amino acids 513–613 of PAPSS2, thus not suitable for
detection of p.W462Cfs*3. Expression of p.W462Cfs*3 was
confirmed at the mRNA level by real-time PCR using the
Hs00989921_m1TaqMan probe for PAPSS2 (Life
Technologies).
To test the impact of ubiquitination on the expression levels
of the p.T48R and p.G270D mutants, these were separately ex-
pressed in HEK293 cells, followed by 6-hour incubation with
10Mof the proteasome inhibitorMG-132 (Sigma) dissolved in
dimethylsulfoxide or dimethylsulfoxide alone.
DHEA challenge test
We employed our previously established in vivo physiology
assessment tool, the DHEA challenge test (18, 19), to study in
vivo DHEA sulfation and androgen synthesis in the two affected
brothers and their heterozygous parents; the sister did not par-
ticipate because she continued on an oral contraceptive, which
precluded detailed analysis of androgen status. In brief, after
obtaining written informed consent and with approval from the
local ethics committee, all four individuals underwent blood
sampling at baseline (9 AM) and 30, 60, 90, 120, 180, and 240
minutes after the oral administration of 100mgDHEA. All four
participants collected two consecutive 24-hour urine samples,
the first during the 24 hours preceding the DHEA challenge test,
and the second starting at the time of DHEA administration.
Serum and urine steroid measurements
Serum steroids were measured by liquid chromatography/
tandemmass spectrometry employing aWaters Xevomass spec-
trometerwithAcquityuPLCsystemasdescribedpreviously (20).
Inbrief, serumsteroidoximeanalysis,which facilitates enhanced
detection of DHEA by formation of oxime derivatives of the
steroid oxo-groups (21), was employed for the measurement of
DHEA, androstenedione,T, andDHTandcarriedout inpositive
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mode,whereasmeasurementof serumDHEASwasperformed in
negative mode. DHEA, androstenedione, T, and DHT were ex-
tracted from serum via liquid-liquid extraction followed by der-
ivatization into steroid oximes. Steroids were identified by
matching retention times and two mass transitions in compari-
son to deuterated reference compounds.
Urinary steroidmetabolite excretion analysis was carried out
by quantitative gas chromatography/mass spectrometry in se-
lected-ion-monitoring analysis mode, as described previously
(22). Inbrief, free andconjugatedurinary steroidswere extracted
by solid-phase extraction, and the conjugateswere enzymatically
hydrolyzed, followed by recovery of the hydrolyzed steroids by
Sep-Pak (Waters) extraction. Specifically, we quantified 5-re-
duced androsterone and 5-reduced etiocholanolone, the two
majormetabolites of active androgens,whichwere used to assess
net systemic 5-reductase activity by calculating the ratio of an-
drosterone/etiocholanolone (An/Et). We also measured urinary
DHEA,which represents the sum of urinaryDHEA andDHEAS
excretion, which cannot be distinguished with this method be-
cause the hydrolysis step removes the sulfate group.However, in
preceding experiments (data not shown)we found that99%of
urinary DHEA originates from DHEAS, ie, proportionate to
their respective circulating serum concentrations in the nano-
molar andmicromolar range, respectively. Thus, for clarity pur-
poses, we have labeled the sum of urinary DHEA andDHEAS in
results and figures as urinary DHEAS.
Statistical analysis
SPSS version 21 software (SPSS Inc) was used for data anal-
ysis. All data were expressed as mean  SD unless otherwise
stated. Independent samples t tests or Mann-Whitney tests were
used as appropriate for comparison between two groups. Dif-
ferences were considered statistically significant at P  .05.
Results
Identification of novel PAPSS2 mutations
FGFR3 and COL2A1 mutations as distinct causes of
the disproportionate short stature had been excluded by
direct sequencing during childhood. When the affected
brothers were 17 and 15 years old, whole exome sequenc-
ing was undertaken in all five family members. This iden-
tified compound heterozygosity for two novel PAPSS2
mutations in both boys: a missense mutation (c.809GA;
p.Gly270Asp; p.G270D) and a frameshift mutation
(c.1369del; p.W462Cfs*3). The mother was identified as
a heterozygous carrier of p.W462Cfs*3, whereas the fa-
ther and the sister were heterozygous for p.G270D.
In silico analysis of the predicted mutant PAPSS2
proteins
Both novel mutations affect the ATP sulfurylase do-
mainof thePAPSS2protein.Thep.W462Cfs*3 frameshift
mutationwill result in a severely truncated protein (Figure
1B). The p.G270Dmissensemutation affects a buried gly-
cine residue within the ATP sulfurylase domain (Figure
1C),which is positioned in a short andbent-strandof the
PAPSS2 protein, 25Å apart from the bound adenosine
5-phosphosulfate nucleotide in the 1XNJ structure of
PAPSS1 (12) (http://www.rcsb.org/pdb/explore/explore.do?
structureId	1xnj). This glycine is invariant in an alignment
of 101 vertebrate and invertebrate PAPS synthases (15). Ex-
changing this highly conserved, small amino acid for a larger
and negatively charged aspartic acid, as in p.G270D, is
highly likely to impact on protein stability and function.
In vitro functional analysis of the mutant PAPSS2
proteins
In vitro analysis of DHEA sulfation capacity after
coexpression of wild-type and mutant PAPSS2 with
SULT2A1showeda significant reduction forp.G270D, sim-
ilar to the previously describedp.T48Rmutant (4), retaining
some residual catalytic activity (Figure 2A). By contrast, co-
expression of SULT2A1 with the p.W462Cfs*3 mutant al-
most completely abolished DHEA sulfation (Figure 2A).
Western blot analysis confirmed equal SULT2A1 expres-
sion; however, the missense mutants p.T48R and p.G270D
consistently showed reduced protein expression (Figure 2B),
whereas mRNA expression levels determined by real-time
PCRwere similar (data not shown). Therefore, we reasoned
that both mutations might result in destabilization of the
resulting mutant PAPSS2 proteins, leading to accelerated
degradation by the ubiquitin-proteasome system. To test
this, we investigated whether mutant protein expression
could be enhanced by the proteasome inhibitor MG-132.
This was indeed the case (Figure 2C), confirming enhanced
ubiquitination as an explanation for the observed reduced
expression of the mutant proteins.
In vivo analysis of DHEA sulfation by the DHEA
challenge test
The two brothers carrying compound heterozygous
PAPSS2 mutations and their heterozygous parents under-
went in vivo assessment to scope their capacity for DHEA
sulfation and androgen synthesis, utilizing an oral chal-
lenge with 100 mg DHEA with frequent serum sampling
and 24-hour urine collection before and after DHEA ad-
ministration (Figure 3).
At baseline, serum DHEAS was decreased in the two
patients and their mother, who carries the major loss-of-
function mutation p.W462Cfs*3, whereas the father
(heterozygous for p.G270D) had normal DHEAS levels.
SerumDHEAwas in the higher normal range, and Twere
within the normal range for age and sex. Urinary steroid
metabolite excretion analysis revealed a significantly en-
hanced baseline 5-reductase activity in both patients, as
represented by the ratio of 5-reduced over 5-reduced
androgen metabolites, androsterone/etiocholanolone
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(An/Et) (Table 1). Similarly, their baseline excretion of
5-reduced androgens was increased, whereas their uri-
naryDHEAS excretionwas very low. Androgen excretion
in the parents was normal, except for a very low DHEAS
excretion and a high 5-reductase activity in the mother
(Table 1).
After administration of DHEA, both patients and their
mother had a subnormal rate of DHEAS generation,
whereas serumDHEAS in the father increased to the lower
reference range (Figure 3A). SerumDHEA peaked in both
patients well above the reference range, whereas the par-
ents showed increases comparable to controls (Figure 3B).
Serum DHEA/DHEAS ratios were highly increased
throughout the challenge test in both affected boys,
whereas their father showed values similar to healthy con-
trols, and the mother’s results ranged in between (Figure
3C). Serum after DHEA did not differ from levels in
healthy controls (Figure 3D). Serum DHT increased after
oral DHEA in both boys, which was not observed in their
parents. Area under the curve analysis showed reduced
values for DHEAS in both patients and their mother (Ta-
ble 2).
Urine steroid analysis after administration of DHEA
revealed significantly reduced generation of DHEAS and
enhanced output of androsterone, themajormetabolite of
DHT, in both patients and their mother. By contrast, the
father showed excretion patterns comparable to controls
(Figure 3E). Androsterone excretion in the two boys was
2.6-fold higher than in their father, whereas etio-
cholanolone excretion was normal (Table 1); urinary ex-
cretion of 5-17-hydroxypregnanolone, indicative of the
alternative androgen pathway (22), did not increase after
DHEA administration (data not shown). After DHEA in-
gestion, the mother showed reduced DHEAS generation
and increased androsterone generation compared to
healthy controls (Table 1). The An/Et ratio was signifi-
cantly raised in both patients and their mother, indicative
of increased 5-reductase activity.
Discussion
Here we carried out an integrated in vitro and in vivo
analysis in a family with two brothers affected by PAPSS2
deficiency due to compound heterozygosity for two novel
PAPSS2 mutations, p.W462Cfs*3s and p.G270D; their
parents and sister were heterozygous carriers.
In silico analysis predicted an obvious deleterious im-
pact of the frameshift p.W462Cfs*3mutationdue to trun-
cation of the PAPSS2 ATP sulfurylase domain. This was
confirmed in our in vitro cell-based assay, whereas the
p.G270D missense mutant exhibited some residual activ-
Figure 2. Functional in vitro assessment of the mutant PAPSS2
proteins. A, Residual enzyme activity expressed as percentage of
wild-type (WT) activity, defined as 100%, based on measurements
of the conversion of DHEA to DHEAS in HEK293 cells cotransfected
with SULT2A1 and WT or mutant PAPSS2. Error bars represent the
mean  SEM of three independent triplicate experiments. B,
Representative Western blot demonstrating equal loading and equal
SULT2A1 protein expression, but significantly lower expression of
mutant PAPSS2 proteins in HEK293 cells cotransfected with
SULT2A1 and WT or mutant PAPSS2. C, Treatment with the
proteasome inhibitor MG-132 enhances protein expression of the
PAPSS2 mutants p.T48R and p.G270D, confirming increased
ubiquitination of the mutant proteins.
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ity. However, Western blotting demonstrated reduced
protein expression for p.G270D and the previously char-
acterized missense mutation p.T48R (4). This suggests
that the mutant proteins are able to maintain some func-
tion but are subject to accelerated degradation due to re-
duced protein stability. We confirmed this assumption by
demonstrating that inhibition of ubiquitination stabilized
the mutant proteins in vitro; thus, enhanced ubiquitina-
Figure 3. DHEA sulfation and androgen synthesis after an oral challenge with 100 mg DHEA. A–C, Serum concentrations of DHEAS (A), DHEA
(B), and the ratio of serum DHEA/DHEAS (C) in the two brothers with compound PAPSS2 mutations (closed symbols) and their heterozygous
parents (mother, empty circle; father, empty square) in comparison to healthy female controls (n 	 20). D, Serum androstenedione after DHEA in
patients, parents and healthy controls. E, Percentage of 24-hour urinary DHEAS excretion in relation to active androgen metabolite excretion after
oral DHEA administration and the percentage of 5-reduced androsterone to 5-reduced etiocholanolone excretion, demonstrating reduced
DHEAS generation and enhanced production of 5-reduced androgens in the patients and their mother. The excretion pattern in the father
resembled that observed in healthy controls (n 	 8).
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tion represents a mechanism likely to contribute to the
disruption of enzymatic activity.
Interestingly, the two affected boys had primarily pre-
sented with a severe bone phenotype, SEMD, and no ap-
parent evidence of androgen excess. This phenotypic pre-
sentation is very similar to the first reported family with
PAPSS2 deficiency, the consanguineous Pakistani family
with 16 individuals affected by overt SEMD (5, 6). The
bone phenotype is thought to be due to impaired pro-
teoglycan sulfation disrupting extracellularmatrix forma-
tion. The overt SEMD phenotype in the two current pa-
tients contrasts with the phenotype in the young girl we
previously described (4), who presented with clinical and
biochemical signs of androgen excess, manifesting as pre-
mature adrenarche and PCOS, but very mild bone abnor-
malities only visible on x-ray. However, all three patients
had low circulating DHEAS, suggesting that in vivo
DHEA sulfotransferase activity was disrupted, which
should result in enhanced androgen generation from
DHEA.
To examine the genotype-phenotype variation in more
detail, we summarized all reported cases with PAPSS2 de-
ficiency (Table 3). Three recent publications (8–10) have
added 24 additional individuals, yielding a total of 43
patients with clinical and radiological phenotype descrip-
tion, whereas functional in vitro analysis of mutant pro-
tein activity was only provided by this study and our pre-
vious study (4). Table 3 illustrates that in PAPSS2
deficiency, four different bone phenotype variants are ob-
served: 1) overt SEMDwithboth vertebrae and longbones
affected (n 	 23); 2) overt brachyolmia with dysplastic
changes confined to the spine (n 	 15); 3) overt brachy-
olmia with dysplastic changes confined to the spine with
additional minimal epimetaphyseal changes only visible
on x-ray (n 	 4); and 4) subclinical brachyolmia with
radiological changes only, as observed in the first patient
we described (4).
Only 16 of the 43 patients reported to date were
assessed for androgen excess; clinical signs including
premature adrenarche and PCOS were reported for six
of them (Table 3). SerumDHEASwasmeasured in eight
patients and invariably found to be low. Circulating
androgens were measured in 10 individuals and in-
creased in two female patients, whereas eight patients
Table 1. Urinary Steroid Metabolite Excretion at Baseline and After Oral Administration of 100 mg DHEA in the
Two Brothers Affected by PAPSS2 Deficiency, in Their Heterozygous Parents, and in Healthy Controls
Urinary Steroid Metabolite
P1,
G270D/
W462Cfs*3
P2,
G270D/
W462Cfs*3
Father,
G270D/
WT
Mother,
WT/
W462Cfs*3
Postpubertal
Boys, n  10
Adult Men,
n  21
Adult Women,
n  30
Adult Women,
n  8
Age, y 17.6 15.1 48 43 14–19 25–48 25–49 23–39
24-h Urine excretion (g/24 h) at
baseline
Androsterone 5751 4325 4450 1249 2491 (986–4928) 2286 (1332–7672) 1163 (324–2819) 893 (150–1746)
Etiocholanolone 1363 746 4819 597 1663 (313–2393) 1958 (613–5981) 1199 (507–3205) 893 (94–1990)
DHEAS 45 21 602 63 94 (31–1170) 1550 (60–6598) 280 (57–4697) 679 (49–4077)
An/Et ratio 4.22 5.80 0.92 2.09 1.71 (0.95–3.15) 1.30 (0.67–3.04) 1.03 (0.35–2.25) 1.11 (0.73–1.60)
24-h Urine excretion (g/24 h) after oral
ingestion of 100 mg DHEA
Androsterone 35 755 35 603 13 787 12 888 4556 (778–9756)
Etiocholanolone 12 472 5982 14 650 6579 5728 (2516–12 647)
DHEAS 415 456 3444 301 6064 (463–27 835)
An/Et ratio 2.87 5.95 0.94 1.96 0.77 (0.27–1.11)
Abbreviation: WT, wild-type. Data for healthy controls are expressed as median (range).
Table 2. Area Under the Curve of Four Sampling Hours (AUC0–4 h) for Serum DHEAS, DHEA, Androstenedione, T,
and DHT After Oral Administration of 100 mg DHEA at Time 0 Min in the Two Brothers With PAPSS2 Deficiency,
Their Heterozygous Parents, and Healthy Female Controls
Steroid AUC0–4 h
P1,
G270D/W462Cfs*3
P2,
G270D/W462Cfs*3
Father,
G270D/WT
Mother,
WT/W462Cfs*3
Healthy Female
Controls, n  20
Age, y 17.6 15.1 48 43 21–45
DHEAS, mol/Lh 517 442 2268 1116 4356 (2426–9145)
DHEA, nmol/Lh 10 646 8885 5516 4688 6667 (3755–14 604)
Androstenedione,
nmol/Lh
2240 1867 1825 1789 1794 (1031–3120)
T, nmol/Lh 6320 3639 7343 464 341 (72–850)
DHT, nmol/Lh 1019 983 688 a a
Abbreviation: WT, wild-type.
a Serum DHT concentrations measured with liquid chromatography/tandem mass spectrometry were below the limit of detection in female
controls. DHT levels in the heterozygous mother were detected, but below the limit of quantitation; therefore, no numbers are provided here.
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had normal androgens (fourmales, four females) (Table
3). Although circulating androgens were normal in the
two affected male patients in this study, urinary steroid
metabolite analysis revealed increased 5-reduced an-
drogens in both of them, indicative of enhanced gener-
ation of active androgens in peripheral tissues from
DHEA. We confirmed this employing oral administra-
tion of the androgen precursor DHEA to assess DHEA
sulfation and androgen synthesis capacity, which dem-
onstrated that in the two patients, DHEAwas converted
to active androgens at a much higher rate than in their
father or in healthy controls. The biological conse-
quences of this androgen excess will need to be moni-
tored prospectively, and it is interesting to note that
neither boy had signs of premature adrenarche. Our
control group consisted of adult women; however, we
demonstrated previously that the conversion pattern to-
ward DHEA, DHEAS, and after oral DHEA is identical
in men and women (18, 23). In healthy men, DHEA
administration does not elicit increases in T or DHT
(23); therefore, it is interesting to note that both patients
showed a clear increase in circulating DHT after oral
DHEA. Using an oral DHEA challenge as a dynamic
test, we provided the first direct functional in vivo ev-
idence that impaired DHEA sulfation results in andro-
gen excess.
Themotherof the twopatients studiedhere reported clin-
ical features consistent with a PCOS phenotype, specifically
chronic anovulation requiring ovulation induction. Andro-
gen analysis showed evidence of enhanced 5-reductase ac-
tivity at baseline and increased 5-reduced androgen pro-
duction after the oral DHEA challenge, with lowDHEAS at
baseline and subnormal DHEAS generation after DHEA.
The mother of our first patient (4) had actually reported a
history of PCOSwith oligomenorrhea and anovulation, but
at the timehadnotprovidedserumorurine formoredetailed
androgen analysis. Coincidentally, both mothers were
heterozygous carriers of a major loss-of-function PAPSS2
mutation, and thus it appears reasonable to assume that
heterozygosity for a mutant allele does not only result in a
subclinical phenotypewith lowDHEAS but can also impact
clinicallywith features resemblingPCOS.Tworecent studies
lookedat the associationof commongenetic variants (minor
allele frequency [MAF]  5%) in SULT2A1 and PAPSS2
with androgen status (24, 25); future studies with a more
detailed phenotyping and genotyping approach will need to
investigate impaired DHEA sulfation as a predisposing fac-
tor to PCOSby looking for low frequency (MAF5%) and
rare variants (MAF 0.5%).
In summary, we have presented conclusive in vivo
evidence for androgen excess as a consequence of im-
paired DHEA sulfation in PAPSS2 deficiency. Further
Table 3. Genotype-Phenotype Spectrum in the 43 Patients With PAPSS2 Deficiency Reported to Date
First Author,
Year (Ref.) Mutant Allele 1 Mutant Allele 2 Sex
Country of
Origin
Clinical Signs of
Androgen Excess
Serum Androgens
(Routine Biochemistry) Bone Phenotype
Bone
Age
Noordam, 2009 (4) p.T48R p.R329* F Turkey PA, AC, HI, SAa Low DHEAS; high A, T, DHT Subclinical BO Advanced
Iida, 2013 (10) p.L76Q p.R129Lfs*25 F Turkey AC, HI, CM “Normal” (no details) Overt BO Normal
Iida, 2013 (10) p.V540D p.V540D F Turkey AC, HI “Normal” (no details) Overt BO Advanced
Iida, 2013 (10) p.V364Rfs*18 p.V364Rfs*18 F Turkey No NR Overt BO Normal
Iida, 2013 (10) p.R129Lfs*25 p.R129Lfs*25 2 F Turkey No NR Overt BO Advanced
Iida, 2013 (10) p.R129Lfs*25 p.R129Lfs*25 F Turkey No NR Overt BO Normal
Iida, 2013 (10) p.Q211Cfs*11 p.Q211Cfs*11 F Turkey No NR Overt BO Normal
Iida, 2013 (10) c.27  3AC c.27  3AC F Turkey No NR Overt BO Normal
Iida, 2013 (10) p.F125Sfs*24 p.F125Sfs*24 F Syria PP High DHEA Overt BO Advanced
Miyake, 2012 (8) p.A113Gfs*18 p.A113Gfs*18 F Turkey No NR Overt BO NR
Miyake, 2012 (8) p.A113Gfs*18 p.A113Gfs*18 F Turkey No Low DHEAS Overt BO, MEMC Advanced
Miyake, 2012 (8) p.V206Sfs*9 p.R437Gfs*19 F Japan No NR Overt BO, MEMC Advanced
Miyake, 2012 (8) c.381  2delT c.381  2delT F Japan No NR Overt BO, MEMC Advanced
Tüysüz, 2013 (9) p.R329* p.R329* F Turkey HI, OM Low DHEAS, normal DHEA, A, T Overt SEMD NR
Tüysüz, 2013 (9) p.R329* p.R329* F Turkey No Low DHEAS, normal DHEA, A, T Overt SEMD NR
Ahmad, 1998 (6) p.S480* p.S480* 11 M, 5 F Pakistan NR NR Overt SEMD NR
Iida, 2013 (10) p.L76Q p.R129Lfs*25 M Turkey No NR Overt BO Normal
Iida, 2013 (10) p.C43Y p.C43Y M Turkey PA NR Overt BO Advanced
Iida, 2013 (10) p.V364Rfs*18 p.V364Rfs*18 M Turkey No NR Overt BO Advanced
Iida, 2013 (10) p.A113Gfs*18 p.A113Gfs*18 2 M Turkey No NR Overt BO NR
Miyake, 2012 (8) p.A113Gfs*18 p.A113Gfs*18 M Turkey No NR Overt BO Delayed
Miyake, 2012 (8) p.K161Rfs*6 p.I221Sfs*40 M Korea No NR Overt BO, MEMC Advanced
Tüysüz, 2013 (9) p.R329* p.R329* 3 M Turkey No Low DHEAS, normal DHEA, A, T Overt SEMD NR
Present study p.G270D p.W462Cfs*3 2 M Netherlands Nob Low DHEAS, normal DHEA, A, T Overt SEMD Delayed
Abbreviations: F, female; M, male; NR, not reported; PA, premature adrenarche; AC, acne; HI, hirsutism; SA, secondary amenorrhea; CM,
clitoromegaly; PP, precocious puberty; OM, oligomenorrhea; A, androstenedione; BO, brachyolmia (short trunk-short stature due to platyspondyly);
MEMC, minimal epimetaphyseal changes; SEMD, spondyloepimetaphyseal dysplasia (brachyolmia plus additional clinically overt epimetaphyeseal
changes). Overt indicates clinical and radiological changes, and subclinical indicates radiological changes only. Mutation nomenclature is according
to Human Genome Variation Society convention and employs PAPSS2 reference sequence NM_001015880.1.
a Mother reported PCOS with oligomenorrhea and anovulation.
b Mother reported chronic anovulation requiring ovulation induction with clomiphene for conception; older sister had primary amenorrhea.
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studies are needed to determine the effect on drug me-
tabolism in affected patients because sulfation is a key
process in the inactivation of drugs and xenobiotics,
which may explain the multiple drug intolerances re-
ported by themother. Studies in PCOS cohorts will need
to look more closely at the pattern of androgen excess
as a differentiating factor, with mounting evidence that
androgen status is closely linked to metabolic risk in
PCOS patients (20).
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